S1200: Acupuncture, Sham Acupuncture, or Wait List for Joint Symptoms Related to Aromatase Inhibitors in Pts W/Early-Stage Breast Cancer



Status:Completed
Conditions:Breast Cancer, Cancer, Chronic Pain
Therapuetic Areas:Musculoskeletal, Oncology
Healthy:No
Age Range:18 - Any
Updated:10/4/2018
Start Date:March 2012
End Date:May 2018

Use our guide to learn which trials are right for you!

Randomized Blinded Sham- and Waitlist-Controlled Trial of Acupuncture for Joint Symptoms Related to Aromatase Inhibitors in Women With Early Stage Breast Cancer

RATIONALE: Acupuncture may help relieve joint pain.

PURPOSE: This randomized phase III trial studies acupuncture to see how well it works
compared to sham acupuncture or waitlist in treating patients with joint pain related to
aromatase inhibitors in patients with early-stage breast cancer.

OBJECTIVES:

Primary

- To determine whether true acupuncture administered twice weekly for 6 weeks (8-12
sessions) compared to sham acupuncture and waitlist control causes a significant
reduction in joint pain related to aromatase inhibitors (AIs) in women with early-stage
breast cancer as measured by the Brief Pain Inventory-Short Form (BPI-SF) worst pain
score at 6 weeks.

Secondary

- To investigate the effects of true acupuncture administered twice weekly for 6 weeks
(8-12 sessions) followed by 6 weekly treatments (4-6 sessions) of maintenance (12-18
sessions total over 12 weeks) compared to sham acupuncture and waitlist control in this
study population; the evaluations at 12 and 24 weeks are to determine the benefit of
additional 6 weekly acupuncture treatments for maintenance and to determine the
durability of response after stopping acupuncture, respectively; the evaluation at 52
weeks is to determine the long-term effects of acupuncture and adherence to AIs.

- To evaluate the effects of acupuncture on the BPI-SF worst pain, worst stiffness, pain
severity, and pain-related interference scores at 6, 12, 16, 20, 24, and 52 weeks.

- To evaluate the effects of acupuncture on Western Ontario and McMaster Universities
Osteoarthritis (WOMAC) index (pain, stiffness, and function) for the hips and knees at
6, 12, 24, and 52 weeks.

- To evaluate the effects of acupuncture on Modified-Score for the Assessment and
Quantification of Chronic Rheumatoid Affections of the Hands (M-SACRAH) (pain,
stiffness, and function) at 6, 12, 24, and 52 weeks.

- To evaluate the effects of acupuncture on the PROMIS Pain Impact-Short Form (PROMIS
PI-SF) at 6, 12, 24, and 52 weeks.

- To evaluate the effects of acupuncture on quality of life (QOL) as assessed by the
Functional Assessment of Cancer Therapy-Endocrine Subscales (FACT-ES) at 6, 12, 24, and
52 weeks.

- To evaluate the effects of acupuncture on functional testing with grip strength and
"Timed Get Up and Go" (TGUG) test at 6, 12, 24, and 52 weeks.

- To evaluate the effects of acupuncture on analgesic and opioid use at 2, 4, 6, 12, 16,
20, 24, and 52 weeks.

- To evaluate the effects of acupuncture on self-reported AI adherence at 12, 24, and 52
weeks.

- To assess AI adherence via urine AI metabolites at baseline, 24, and 52 weeks.

- To evaluate the effects of acupuncture on serum hormones (estradiol, FSH, LH) and
inflammatory biomarkers (serum TNFα, IL-6, IL-12, CRP, and urine c-telopeptides of Type
II collagen (CTX-II) at 6, 12, and 24 weeks. (Exploratory)

- To evaluate whether polymorphisms in CYP19A1 aromatase gene predict severity of
AI-related joint symptoms. (Exploratory)

- To assess the safety and tolerability of acupuncture in this study population.

OUTLINE: This is a multicenter study. Patients are stratified according to study site.
Patients are randomized to 1 of 3 treatment arms.

- Arm I: Patients receive acupuncture twice weekly for 6 weeks and then once weekly for 6
weeks.

- Arm II: Patients receive sham acupuncture twice weekly for 6 weeks and then once weekly
for 6 weeks.

- Arm III: Patients are assigned to a waiting list for 12 weeks. Patients complete the
Brief Pain Inventory-Short Form (BPI-SF), the Western Ontario and McMaster Universities
Osteoarthritis (WOMAC) Index, the Modified-Score for the Assessment and Quantification
of Chronic Rheumatoid Affections of the Hands (M-SACRAH), the PROMIS Pain Impact-Short
Form (PROMIS PI-SF), the FACT-ES Trial Outcome Index, and the Aromatase Inhibitor Usage
Form questionnaires at baseline and at 6, 12, 24 and 52 weeks.

Patients undergo blood sample collection at baseline and at 6, 12, and 24 weeks for serum
hormones (estradiol, FSH, LH) levels, inflammatory markers (TNFα, IL-6, IL-12, CRP), and DNA
analysis. Urine samples are also collected at baseline and at 24 and 52 weeks for
c-telopeptides of Type II collagen and aromatase inhibitor metabolites analysis.

After completion of study treatment, patients are followed up at 24 and 52 weeks.

DISEASE CHARACTERISTICS:

- Patients must be women with histologically confirmed primary invasive carcinoma of the
breast (Stage I, II, or III) with no evidence of metastatic disease (M0); patients
must have undergone modified radical mastectomy or breast-sparing surgery; patients
must have recovered from all side-effects of the surgery

- Patients must be positive for estrogen receptor (ER) and/or progesterone receptor
(PgR) as determined by institutional standard

- Patients must currently be taking a third-generation aromatase inhibitor (AI) -
anastrozole, letrozole, or exemestane for at least the previous 90 days prior to
registration with plans to continue for at least an additional 1 year after
registration; patients may have switched AIs provided that they have been on a stable
dose for at least 90 days; concurrent trastuzumab (Herceptin) is allowed

- Patients must have completed the S1200 Brief Pain Inventory-Short Form (BPI-SF) within
14 days prior to registration; patients must have a worst pain score of at least 3 on
the Brief Pain Inventory (item #2) that has started or increased since starting AI
therapy

- Patients must be willing to submit blood and urine samples for serum hormones
(estradiol, FSH, LH), inflammatory biomarkers (serum TNFα, IL-6, IL-12, CRP and urine
CTX-II), urine AI metabolites, and DNA analysis (CYP19A1), and must be given the
option to consent to use of remaining specimens for future translational medicine
studies; baseline samples must be obtained prior to beginning intervention

PATIENT CHARACTERISTICS:

- Patients must be postmenopausal, as defined by at least one of the following:

- ≥ 12 months since the last menstrual period

- Prior bilateral oophorectomy

- Current use of a gonadotropin-releasing hormone (GnRH) agonist

- Previous hysterectomy with one or both ovaries left in place (or previous
hysterectomy in which documentation of bilateral oophorectomy is unavailable) AND
follicle-stimulating hormone (FSH) values consistent with the institutional
normal values for the postmenopausal state; if patient is under the age of 55,
FSH levels must be obtained within 28 days prior to registration

- Patients must have a Zubrod performance status of 0 to 1

- Patients must not have a severe bleeding disorder

- Patients must not have concurrent medical/arthritic disease that could confound or
interfere with evaluation of pain or efficacy including: inflammatory arthritis (e.g.,
rheumatoid arthritis, systemic lupus, spondyloarthropathy, psoriatic arthritis,
polymyalgia rheumatica), gout, episodes of acute monoarticular arthritis clinically
consistent with pseudogout, Paget disease affecting the study joint (knees/hands), a
history of septic arthritis or avascular necrosis or intra-articular fracture of the
study joint, Wilson disease, hemochromatosis, alkaptonuria, or primary
osteochondromatosis

- Patients must not have a history of bone fracture or surgery of the afflicted knees
and/or hands within 6 months prior to registration

- Patients must not have a history of illness that, in the opinion of the investigator,
might confound the results of the study or pose additional risk to the patient

- Patients must be able to complete study questionnaires in English or Spanish

- No other prior malignancy is allowed except for adequately treated basal cell or
squamous cell skin cancer, in situ cervical cancer, ductal carcinoma in situ [DCIS],
adequately treated Stage I or II cancer from which the patient is currently in
complete remission, or any other cancer for which the patient has been disease-free
for > 5 years

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- Patients must not have had prior acupuncture treatment within the past 12 months or
for AI-induced joint symptoms at any time

- Patients must not be on narcotics within 14 days of registration

- Patients must not have received oral corticosteroids, intramuscular corticosteroids,
or intra-articular steroids within 28 days prior to registration

- Patients must not have received topical analgesics (e.g., capsaicin preparations) or
any other analgesics (e.g., opiates or tramadol, with the exception of nonsteroidal
anti-inflammatory drugs [NSAIDs] and acetaminophen) within 14 days prior to
registration

- Patients must not have received or implemented any other medical therapy, alternative
therapy, or physical therapy for the treatment of joint pain/stiffness within 28 days
prior to registration; therapeutic massage is allowed
We found this trial at
47
sites
100 E Idaho St
Boise, Idaho 83712
(208) 381-2711
Principal Investigator: Paul G. Montgomery
Phone: 800-845-4624
Saint Luke's Mountain States Tumor Institute For more than 100 years, St. Luke
?
mi
from
Boise, ID
Click here to add this to my saved trials
1100 Fairview Avenue North
Seattle, Washington 98109
206-667-4584
Principal Investigator: Julie R. Gralow
Phone: 800-804-8824
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium The Fred Hutchinson/University of Washington Cancer...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
825 Eastlake Ave E
Seattle, Washington 98109
(206) 288-7222
Principal Investigator: Julie R. Gralow
Phone: 800-804-8824
Seattle Cancer Care Alliance Seattle Cancer Care Alliance (SCCA) is a cancer treatment center that...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Antioch, California 94531
Principal Investigator: Louis Fehrenbacher
Phone: 626-564-3455
?
mi
from
Antioch, CA
Click here to add this to my saved trials
265 Fremont St
Battle Creek, Michigan 49017
(269) 245-8166
Principal Investigator: Gilbert D. Padula
Phone: 616-685-5225
Bronson Battle Creek As a proud member of the Battle Creek community, we believe everyone...
?
mi
from
Battle Creek, MI
Click here to add this to my saved trials
Big Rapids, Michigan 49307
?
mi
from
Big Rapids, MI
Click here to add this to my saved trials
Burlington, Massachusetts 01805
Principal Investigator: Corrine L. Zarwan
Phone: 781-744-8027
?
mi
from
Burlington, MA
Click here to add this to my saved trials
39400 Paseo Padre Parkway
Fremont, California 94538
(510) 248-3000
Principal Investigator: Louis Fehrenbacher
Phone: 626-564-3455
Kaiser Permanente - Fremont You can rely on Kaiser Permanente for quality care, delivered with...
?
mi
from
Fremont, CA
Click here to add this to my saved trials
Grand Rapids, Michigan 49503
Principal Investigator: Gilbert D. Padula
Phone: 616-685-5225
?
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
25 Michigan St. NE, Suite 3100
Grand Rapids, Michigan 49503
(616) 391-1230
Grand Rapids Clinical Oncology Program GRCOP initially formed to develop community cancer patient management guidelines....
?
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
100 Michigan St NE
Grand Rapids, Michigan 49503
(616) 391-1774
Principal Investigator: Gilbert D. Padula
Phone: 616-685-5225
Spectrum Health at Butterworth Campus Butterworth Hospital is one of four facilities that make up...
?
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Greenville, South Carolina 29601
Principal Investigator: Mark A. O'Rourke
Phone: 864-241-6251
?
mi
from
Greenville, SC
Click here to add this to my saved trials
Greenville, South Carolina 29605
Principal Investigator: Mark A. O'Rourke
Phone: 864-241-6251
?
mi
from
Greenville, SC
Click here to add this to my saved trials
Greenville, South Carolina 29605
Principal Investigator: Mark A. O'Rourke
Phone: 864-241-6251
?
mi
from
Greenville, SC
Click here to add this to my saved trials
Greenville, South Carolina 29615
Principal Investigator: Mark A. O'Rourke
Phone: 864-241-6251
?
mi
from
Greenville, SC
Click here to add this to my saved trials
701 Grove Rd
Greenville, South Carolina 29605
(864) 455-7000
Principal Investigator: Mark A. O'Rourke
Phone: 864-241-6251
Greenville Memorial Hospital Greenville Memorial Medical Campus is a regional referral center for the diagnosis...
?
mi
from
Greenville, SC
Click here to add this to my saved trials
Greer, South Carolina 29650
Principal Investigator: Mark A. O'Rourke
Phone: 864-241-6251
?
mi
from
Greer, SC
Click here to add this to my saved trials
24800 SE Stark St
Gresham, Oregon 97030
(503) 674-1122
Legacy Mount Hood Medical Center Legacy Mount Hood Medical Center, East County's full-service community hospital,...
?
mi
from
Gresham, OR
Click here to add this to my saved trials
1441 Eastlake Ave
Los Angeles, California 90033
(323) 865-3000
Principal Investigator: Agustin A. Garcia
Phone: 323-865-0451
U.S.C./Norris Comprehensive Cancer Center The USC Norris Comprehensive Cancer Center, located in Los Angeles, is...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
?
mi
from
Meridian, ID
Click here to add this to my saved trials
Muskegon, Michigan 49444
Principal Investigator: Gilbert D. Padula
Phone: 616-685-5225
?
mi
from
Muskegon, MI
Click here to add this to my saved trials
630 W 168th St
New York, New York
212-305-2862
Principal Investigator: Dawn L. Hershman
Phone: 212-305-8615
Columbia University Medical Center Situated on a 20-acre campus in Northern Manhattan and accounting for...
?
mi
from
New York, NY
Click here to add this to my saved trials
Oakland, California 94611
Principal Investigator: Louis Fehrenbacher
Phone: 626-564-3455
?
mi
from
Oakland, CA
Click here to add this to my saved trials
1015 NW 22nd Ave
Portland, Oregon 97210
(503) 413-7711
Legacy Good Samaritan Hospital and Medical Center Located in the heart of Northwest Portland, Legacy...
?
mi
from
Portland, OR
Click here to add this to my saved trials
Redwood City, California 94063
Principal Investigator: Louis Fehrenbacher
Phone: 626-564-3455
?
mi
from
Redwood City, CA
Click here to add this to my saved trials
300 N Patterson Rd
Reed City, Michigan 49677
(231) 832-3271
Principal Investigator: Gilbert D. Padula
Phone: 616-685-5225
Spectrum Health Reed City Hospital At Spectrum Health Reed City Hospital, you have access to...
?
mi
from
Reed City, MI
Click here to add this to my saved trials
Richmond, California 94801
Principal Investigator: Louis Fehrenbacher
Phone: 626-564-3455
?
mi
from
Richmond, CA
Click here to add this to my saved trials
Roseville, California 95678
Principal Investigator: Louis Fehrenbacher
Phone: 626-564-3455
?
mi
from
Roseville, CA
Click here to add this to my saved trials
Sacramento, California 95823
Principal Investigator: Louis Fehrenbacher
Phone: 626-564-3455
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
6600 Bruceville Road
Sacramento, California 95823
(916) 688-2000
Principal Investigator: Louis Fehrenbacher
Phone: 626-564-3455
Kaiser Permanente - Sacramento At the Kaiser Permanente South Sacramento Medical Center, you and your...
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
2000 Circle of Hope Dr
Salt Lake City, Utah 84112
(801) 585-0303
Principal Investigator: Anna C. Beck
Phone: 801-581-4477
Huntsman Cancer Institute at University of Utah Huntsman Cancer Institute (HCI) is part of the...
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
San Francisco, California 94115
Principal Investigator: Louis Fehrenbacher
Phone: 626-564-3455
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
San Jose, California 95119
Principal Investigator: Louis Fehrenbacher
Phone: 626-564-3455
?
mi
from
San Jose, CA
Click here to add this to my saved trials
San Leandro, California 94577
Principal Investigator: Louis Fehrenbacher
Phone: 626-564-3455
?
mi
from
San Leandro, CA
Click here to add this to my saved trials
San Rafael, California 94903
Principal Investigator: Louis Fehrenbacher
Phone: 626-564-3455
?
mi
from
San Rafael, CA
Click here to add this to my saved trials
700 Lawrence Expy
Santa Clara, California 95051
(408) 851-1000
Principal Investigator: Louis Fehrenbacher
Phone: 626-564-3455
Kaiser Permanente Medical Center - Santa Clara At Kaiser Permanente Santa Clara, members and patients...
?
mi
from
Santa Clara, CA
Click here to add this to my saved trials
Santa Rosa, California 95403
Principal Investigator: Louis Fehrenbacher
Phone: 626-564-3455
?
mi
from
Santa Rosa, CA
Click here to add this to my saved trials
Seneca, South Carolina 29672
Principal Investigator: Mark A. O'Rourke
Phone: 864-241-6251
?
mi
from
Seneca, SC
Click here to add this to my saved trials
South San Francisco, California 94080
Principal Investigator: Louis Fehrenbacher
Phone: 626-564-3455
?
mi
from
South San Francisco, CA
Click here to add this to my saved trials
Spartanburg, South Carolina 29307
Principal Investigator: Mark A. O'Rourke
Phone: 864-241-6251
?
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Stockton, California 95210
Principal Investigator: Louis Fehrenbacher
Phone: 626-564-3455
?
mi
from
Stockton, CA
Click here to add this to my saved trials
105 Sixth St
Traverse City, Michigan 49684
(231) 935-5000
Principal Investigator: Gilbert D. Padula
Phone: 616-685-5225
Munson Medical Center There’s no place quite like northern Michigan, and there is no other...
?
mi
from
Traverse City, MI
Click here to add this to my saved trials
19300 SW 65th Ave
Tualatin, Oregon 97062
(503) 692-1212
Legacy Meridian Park Hospital Legacy Meridian Park Medical Center opened its new Chest Pain Center,...
?
mi
from
Tualatin, OR
Click here to add this to my saved trials
1 Quality Dr
Vacaville, California 95688
(707) 624-4000
Principal Investigator: Louis Fehrenbacher
Phone: 626-564-3455
Kaiser Permanente Medical Center - Vacaville First established in Vallejo in 1945, Kaiser Permanente Napa-Solano...
?
mi
from
Vacaville, CA
Click here to add this to my saved trials
Vallejo, California 94589
Principal Investigator: Louis Fehrenbacher
Phone: 626-564-3455
?
mi
from
Vallejo, CA
Click here to add this to my saved trials
Vancouver, Washington 98686
?
mi
from
Vancouver, WA
Click here to add this to my saved trials
Walnut Creek, California 94596
Principal Investigator: Louis Fehrenbacher
Phone: 626-564-3455
?
mi
from
Walnut Creek, CA
Click here to add this to my saved trials